24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T_H17 pathogenicity and transdifferentiation.

ABSTRACT:

Background

24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (PSC).

Objective

Since PSC strongly associates with T helper-type-like 17 (T_H17)-mediated intestinal inflammation, we explored NorUDCA's immunomodulatory potential on T_H17 cells.

Design

NorUDCA's impact on T_H17 differentiation was assessed using a CD4⁺T_Naive adoptive transfer mouse model, and on intraepithelial T_H17 pathogenicity and transdifferentiation using an αCD3 stimulation model combined with interleukin-17A-fate-mapping. Mechanistic studies used molecular and multiomics approaches, flow cytometry and metabolic assays wit

SUBMITTER: Zhu C 

PROVIDER: S-EPMC12322472 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature